Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...

ADI shares flashed a Golden Cross pattern on July 1, when the 50-day moving average crossed above the 200-day, a classic ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

The largest healthcare stocks by market capitalization are undergoing significant sell-offs. UnitedHealth is still a large ...

Biogen will invest an extra $2 billion to expand its RTP facilities, focusing on AI-driven manufacturing and late-stage ...

AstraZeneca Plc plans to invest $50 billion in the US before 2030, becoming the latest European pharma company to ratchet up ...

Sinopep-Allsino’s share price surged over 70 percent in the first half of last year when it became API supplier to several ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Detailed price information for Harvest Eli Lilly Enhanced High Income S (LLHE-T) from The Globe and Mail including charting and trades.